Determine what populations of children will be targeted in the initial rollout. Download a PDF of this page [PDF, 181KB] to use offline.
At this stage the Ministry of Health (MOH) can engage its stakeholders, such as policy-makers, clinicians, project and funding agencies, implementing partners, civil society organizations and nongovernmental organizations, to decide on the clinical aspects of the use of LPV/r pellets within their system.
Patient Eligibility Recommendations
Specifically, the MOH needs to decide whether the LPV/r pellets should only be considered for newly initiated patients, or whether to switch children under 3 years old who are currently doing well on NVP-containing regimens or other LPV/r formulations.
Country programs are encouraged to consider the following suggestions from the Antiretroviral (ARV) Procurement Working Group when articulating eligibility groups for LPV/r pellets, so as to target the pellets to those patients who need it most:
|Patient Description||Patient Eligibility|
|Patients to be optimized for LPV/r pellets||
|Patients for whom transition to pellets may be delayed||
|Patients for whom LPV/r pellets should NOT be used||
|Additional recommendations for older children||
- ARV Procurement Working Group Memorandum: Re: Available Supply of Paediatric LPV/r formulations and guidance for country procurement [PDF, 259KB]: Memorandum from the ARV Procurement Working Group in April 2017 with information and guidance for country programs planning to procure LPV/r pellets or LPV/r solution.